Can’t-miss studies from SPIRE to ABSORB III and more
ACC.17 is approaching fast. As you sketch out your itinerary at the American College of Cardiology’s 66th Annual Scientific Session, make room for the following key presentations that Cleveland Clinic experts are presenting or closely affiliated with.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Also be sure to stop by Cleveland Clinic’s booth (No. 3227) to chat with our physicians, learn about our C5Research group and explore cardiovascular consulting opportunities for your organization. And don’t miss our complimentary CME dinner symposium, “Consensus and Controversies in the Management of Challenging Patients,” on Thursday evening, March 16.
See you in Washington, D.C.!
Opening Showcase and Joint ACC/JACC Late-Breaking Clinical Trials
Friday, March 17, 8-10 a.m.
Safety and Cardiovascular Event Efficacy of Bococizumab Among 27,000 High-Risk Patients
Lead Cleveland Clinic investigator: Steven Nissen, MD
Late-Breaking Clinical Trials
Saturday, March 18, 10:45-noon
Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: Two-Year Outcomes from the ABSORB III Trial
Presenter and lead Cleveland Clinic investigator: Stephen Ellis, MD
Featured Interventional Clinical Research II
Saturday, March 18, 12:30-1:45 p.m.
Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis from the STS/ACC TVT Registry
Presenter and lead Cleveland Clinic investigator: E. Murat Tuzcu, MD
Moderated Poster Contributions
Sunday, March 19, 12:30-12:40 p.m.
Variable Accuracy of Commercially Available Wearable Heart Rate Monitors
Presenter and lead Cleveland Clinic investigator: A. Marc Gillinov, MD
Advertisement
Advertisement
A sampling of outcome and volume data from our Heart & Vascular Institute
Concomitant AF ablation and LAA occlusion strongly endorsed during elective heart surgery
Large retrospective study supports its addition to BAV repair toolbox at expert centers
Young age, solid tumor, high uptake on PET and KRAS mutation signal risk, suggest need for lobectomy
Surprise findings argue for caution about testosterone use in men at risk for fracture
Residual AR related to severe preoperative AR increases risk of progression, need for reoperation
Findings support emphasis on markers of frailty related to, but not dependent on, age
Provides option for patients previously deemed anatomically unsuitable